SCHEMBL7690876

SCHEMBL7690876

COc1ccc(CCc2[c]ccc(N(C)C)c2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
AOC3 Q16853 1/20 0.49
CYP19A1 P11511 1/20 0.48
ATM Q13315 2/20 0.46
KDM4E B2RXH2 2/20 0.46
POLB P06746 1/20 0.44
CA2 P00918 1/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
SMPD1 P17405 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
STAT3 P40763 1/20 0.41
ABCB1 P08183 1/20 0.41
MAPT P10636 1/20 0.40
DAO P14920 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673825 0.83 CALM1 (0.53) AOC3CALM1
SCHEMBL7674074 0.80 CYP19A1 (0.50) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL7673952 0.77 AOC3 (0.41) AOC3KDM4EALDH1A1DAOCALM1
SCHEMBL1419583 0.75 CALM1 (0.33) CYP3A4ALDH1A1CALM1
SCHEMBL31157848 0.74 CYP19A1 (0.77) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL16641094 0.74 CYP19A1 (0.77) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL10335393 0.73 CYP19A1 (0.81) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL8686211 0.70 KDM4E (0.41) CYP19A1ATMKDM4EALDH1A1
SCHEMBL1107760 0.69 NQO2 (0.63) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL10118317 0.69 CYP1A2 (0.79) CYP1A2CYP3A4CYP2D6BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6395730-B1 CARDIOVASCULAR DISORDERS ICAGEN, INC. 2002-05-28 US disclosed
US-6174908-B1 TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE ICAGEN, INC. 2001-01-16 US disclosed